{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T07:09:12Z","timestamp":1763017752351},"reference-count":40,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2017,7,1]],"date-time":"2017-07-01T00:00:00Z","timestamp":1498867200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["lipidjournal.com","clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2017,7]]},"DOI":"10.1016\/j.jacl.2017.04.121","type":"journal-article","created":{"date-parts":[[2017,5,8]],"date-time":"2017-05-08T18:31:38Z","timestamp":1494268298000},"page":"929-937","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial"],"prefix":"10.1016","volume":"11","author":[{"given":"Harold E.","family":"Bays","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mehul D.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panagiotis","family":"Mavros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dena R.","family":"Ramey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne E.","family":"Tomassini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew M.","family":"Tershakovec","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl A.","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2017.04.121_bib1","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat Med"},{"issue":"1 Suppl","key":"10.1016\/j.jacl.2017.04.121_bib2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jacl.2015.08.002","article-title":"National Lipid Association Annual Summary of Clinical Lipidology 2016","volume":"10","author":"Bays","year":"2016","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2017.04.121_bib3","unstructured":"FDA. Guidance for Industry: Evidence-based review system for the scientific evaluation of health claims \u2013 final. Available at: http:\/\/www.fda.gov\/Food\/GuidanceRegulation\/GuidanceDocumentsRegulatoryInformation\/LabelingNutrition\/ucm073332.htm. Accessed December 23,\u00a02016."},{"key":"10.1016\/j.jacl.2017.04.121_bib4","unstructured":"FDA. Biomarkers used as outcomes in development of FDA-approved therapeutics (October 2007\u2013December 2015). Available at: http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/drugdevelopmenttoolsqualificationprogram\/ucm483052.htm. Accessed December 23,\u00a02016."},{"key":"10.1016\/j.jacl.2017.04.121_bib5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/11591960-000000000-00000","article-title":"Attenuation of rate of change in carotid intima-media thickness by lipid-modifying drugs","volume":"11","author":"Peters","year":"2011","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacl.2017.04.121_bib6","doi-asserted-by":"crossref","first-page":"3251","DOI":"10.1093\/eurheartj\/eht301","article-title":"Stabilization of atherosclerotic plaques: an update","volume":"34","author":"Yl\u00e4-Herttuala","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.04.121_bib7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.atherosclerosis.2015.11.023","article-title":"Changing characteristics of statin-related cIMT trials from 1988 to 2006","volume":"246","author":"Davidson","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.04.121_bib8","doi-asserted-by":"crossref","first-page":"2006","DOI":"10.1016\/j.jacc.2010.05.059","article-title":"Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials","volume":"56","author":"Costanzo","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.04.121_bib9","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2004.09.015","article-title":"Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia","volume":"95","author":"van Wissen","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacl.2017.04.121_bib10","series-title":"PhRMA Web Synopsis, Protocol A2581051, Carotid Atorvastatin Study in Hyperlipidemic Post-Menopausal Women: A Randomized Evaluation of Atorvastatin Versus Placebo (CASHMERE)","year":"2007"},{"key":"10.1016\/j.jacl.2017.04.121_bib11","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1056\/NEJMoa071359","article-title":"Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia","volume":"356","author":"Kastelein","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.04.121_bib12","series-title":"Lipitor US Prescribing Information","author":"Pfizer","year":"2015"},{"key":"10.1016\/j.jacl.2017.04.121_bib13","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1056\/NEJMoa0800742","article-title":"Simvastatin with or without ezetimibe in familial hypercholesterolemia","volume":"358","author":"Kastelein","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.04.121_bib14","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1161\/01.CIR.0000068312.21969.C8","article-title":"Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial","volume":"107","author":"Ballantyne","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.04.121_bib15","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1016\/S0735-1097(02)02610-4","article-title":"Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia","volume":"40","author":"Davidson","year":"2002","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2017.04.121_bib16","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1056\/NEJMe0801608","article-title":"Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?","volume":"358","author":"Brown","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.04.121_bib17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3949\/ccjm.75.7.479","article-title":"Is ezetimibe\/simvastatin no better than simvastatin alone? Lessons learned and clinical implications","volume":"75","author":"Davidson","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jacl.2017.04.121_bib18","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMe0801842","article-title":"Cholesterol lowering and ezetimibe","volume":"358","author":"Drazen","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.04.121_bib19","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jacl.2011.11.007","article-title":"Changes in prescription patterns before and after reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial (ENHANCE) results and expected effects on low-density lipoprotein-cholesterol reduction","volume":"6","author":"Toth","year":"2012","journal-title":"J Clin Lipid"},{"key":"10.1016\/j.jacl.2017.04.121_bib20","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/MLR.0b013e31825517b6","article-title":"Warnings without guidance: patient responses to an FDA warning about ezetimibe","volume":"50","author":"Shrank","year":"2012","journal-title":"Med Care"},{"key":"10.1016\/j.jacl.2017.04.121_bib21","series-title":"Changes in Prescription Patterns Associated with Reporting of Clinical Trial Results","author":"Toth","year":"2013"},{"key":"10.1016\/j.jacl.2017.04.121_bib22","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"25 Suppl 2","key":"10.1016\/j.jacl.2017.04.121_bib23","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on practice guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"key":"10.1016\/j.jacl.2017.04.121_bib24","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170\u00a0000 participants in 26 randomised trials","volume":"376","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.jacl.2017.04.121_bib25","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1001\/jama.299.8.953","article-title":"Critical lessons from the ENHANCE trial","volume":"299","author":"Greenland","year":"2008","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jacl.2017.04.121_bib26","series-title":"Cholesterol Zetia Doesn\u2019t Cut Heart Attack Risk: Study","author":"Edelson","year":"2008"},{"key":"10.1016\/j.jacl.2017.04.121_bib27","doi-asserted-by":"crossref","first-page":"497","DOI":"10.3949\/ccjm.75.7.497","article-title":"Given the ENHANCE trial results, ezetimibe is still unproven","volume":"75","author":"Taylor","year":"2008","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.jacl.2017.04.121_bib28","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jacl.2017.04.121_bib29","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1056\/NEJMoa1300955","article-title":"Effects of extended-release niacin with laropiprant in high-risk patients","volume":"371","author":"Landray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2017.04.121_bib30","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0021-9150(01)00437-3","article-title":"Coadministration of colesevelam hydrochloride with atorvastatin lowers LDL cholesterol additively","volume":"158","author":"Hunninghake","year":"2001","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2017.04.121_bib31","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jama.299.8.885","article-title":"Controversies surround heart drug study: questions about Vytorin and trial sponsors' conduct","volume":"299","author":"Mitka","year":"2008","journal-title":"J Am Med Assoc"},{"key":"10.1016\/j.jacl.2017.04.121_bib32","series-title":"Statement from the American College of Cardiology Related to the ENHANCE Trial","year":"2008"},{"key":"10.1016\/j.jacl.2017.04.121_bib33","series-title":"Congress Sends Letters to ACC and AHA Over ENHANCE Press Release and Industry Funding. Medscape","author":"O\u2019Riordan","year":"2008"},{"key":"10.1016\/j.jacl.2017.04.121_bib34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.ahj.2010.03.004","article-title":"An update on the IMProved reduction of outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design","volume":"159","author":"Califf","year":"2010","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacl.2017.04.121_bib35","article-title":"Should healthy people take cholesterol drugs to prevent heart disease?","author":"Blumenthal","year":"2012","journal-title":"Wall St J"},{"key":"10.1016\/j.jacl.2017.04.121_bib36","series-title":"Top Cardiologist Argues We Should Dial Back on Statins Because of Diabetes Risk","author":"Herper","year":"2012"},{"key":"10.1016\/j.jacl.2017.04.121_bib37","series-title":"Statins and Diabetes\u2014Is There Really a Risk?","author":"LaMattina","year":"2012"},{"key":"10.1016\/j.jacl.2017.04.121_bib38","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1093\/eurheartj\/ehv641","article-title":"Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study","volume":"37","author":"Nielsen","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2017.04.121_bib39","first-page":"e111","article-title":"Clinical consequences of disseminating the rosiglitazone FDA safety warning","volume":"16","author":"Orrico","year":"2010","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.jacl.2017.04.121_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMp0805753","article-title":"Communicating medical news\u2013pitfalls of health care journalism","volume":"360","author":"Dentzer","year":"2009","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417302891?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287417302891?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T00:22:50Z","timestamp":1658103770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287417302891"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,7]]}},"alternative-id":["S1933287417302891"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2017.04.121","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2017,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world data to assess changes in low-density lipoprotein cholesterol and predicted cardiovascular risk after ezetimibe discontinuation post reporting of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2017.04.121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 National Lipid Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}